Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Roger Stupp MD
Roger Stupp MD Advisory Board
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
See All Experts
story of the week
Published in Oncology

Journal Scan / Research · December 25, 2014

TH-302 Plus Gemcitabine Improves Outcomes in Patients With Advanced Pancreatic Cancer

Journal of Clinical Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Journal of Clinical Oncology
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
J. Clin. Oncol 2014 Dec 15;[EPub Ahead of Print], MJ Borad, SG Reddy, N Bahary, HE Uronis, D Sigal, AL Cohn, WR Schelman, J Stephenson, EG Chiorean, PJ Rosen, B Ulrich, T Dragovich, SA Del Prete, M Rarick, C Eng, S Kroll, DP Ryan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated